|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Stock-based compensation | |||||
| Depreciation on property and equipment | |||||
| Non-cash lease expense | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Prepaid expenses and other current assets | |||||
| Income tax receivable | |||||
| Other assets | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Operating lease liabilities | |||||
| Due to Roivant Sciences Ltd. | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Purchases of property and equipment | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement | |||||
| Underwritten Offering | |||||
| Total proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement | |||||
| Payment of offering and private placement costs | |||||
| Proceeds from stock options exercised | |||||
| Net cash provided by financing activities | |||||
| Effect of exchange rate changes on cash and cash equivalents | |||||
| Net change in cash and cash equivalents | |||||
| Cash and cash equivalents – beginning of period | |||||
| Cash and cash equivalents – end of period | |||||
| Supplemental Cash Flow Information | |||||
| Non-cash operating activity | |||||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | |||||
| Supplemental disclosure of cash paid: | |||||
| Income taxes | |||||
Loading...